Frontlight ResearchEarly access
TerminatedPhase 2
This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).
Key facts
- Who runs it
- AnaptysBio, Inc.
- Where
- Anaheim, Ann Arbor, Atlanta, Auburn Hills, Baton Rouge, Baytown, Boise, Cerritos, Charlotte, Clarksville, Dallas, Detroit, Doral, Flossmoor, Fountain Valley, Fremont, Frisco, Hazelwood, Katy, Lancaster, Las Vegas, Lomita, Mason, Merrillville, Methuen, Miami, Nashville, New Albany, Oxnard, Pasadena, Philadelphia, Portland, Saint Joseph, San Antonio, Santa Monica, Spokane, Troy, and Wilmington, United StatesSee the 41 sitesAlso in 6 other countries, 37 sites
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 201 people enrolled
- Started
- 13 Jun 2023
- Ended
- 7 Jan 2025
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ANB032
- Placebo
- Record updated
- 14 February 2025
- Why it stopped
- ANB032 did not meet the primary endpoint in moderate-to-severe atopic dermatitis
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Male or female aged 18 to 65 years and in good general health
- Moderate to severe AD for at least 6 months prior to Randomization
- History of inadequate response to treatment for AD with topical medications or for whom topical treatments are otherwise medically inadvisable
- EASI score ≥ 16 at Screening and at Randomization
- vIGA AD score ≥ 3 at Screening and at Randomization
- AD involved BSA ≥ 10% at Screening and at Randomization
Who cannot take part
- Not able to tolerate SC drug administration
- Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
- Any factors that in the Investigator's opinion would predispose the subject to develop an infection
- Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status
Where in United States
Also in 6 other countries, 37 sites
- Anaheim, CaliforniaHospital not named in the registry
- Ann Arbor, MichiganHospital not named in the registry
- Atlanta, GeorgiaHospital not named in the registry
- Auburn Hills, MichiganHospital not named in the registry
- Baton Rouge, LouisianaHospital not named in the registry
- Baytown, TexasHospital not named in the registry
- Boise, IdahoHospital not named in the registry
- Cerritos, CaliforniaHospital not named in the registry
- Charlotte, North CarolinaHospital not named in the registry
- Clarksville, IndianaHospital not named in the registry
- Dallas, TexasHospital not named in the registry
- Detroit, MichiganHospital not named in the registry
- Doral, FloridaHospital not named in the registry
- Flossmoor, IllinoisHospital not named in the registry
- Fountain Valley, CaliforniaHospital not named in the registry
- Fremont, CaliforniaHospital not named in the registry
- Frisco, TexasHospital not named in the registry
- Hazelwood, MissouriHospital not named in the registry
- Katy, TexasHospital not named in the registry
- Lancaster, CaliforniaHospital not named in the registry
- Las Vegas, NevadaHospital not named in the registry
- AnaptysBio Investigative 10-125Lomita, United States
- Mason, OhioHospital not named in the registry
- Merrillville, IndianaHospital not named in the registry
- Methuen, MassachusettsHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Miami, FloridaHospital not named in the registry
- Nashville, TennesseeHospital not named in the registry
- New Albany, IndianaHospital not named in the registry
- Oxnard, CaliforniaHospital not named in the registry
- Pasadena, CaliforniaHospital not named in the registry
- Philadelphia, PennsylvaniaHospital not named in the registry
- Portland, OregonHospital not named in the registry
- Saint Joseph, MissouriHospital not named in the registry
- San Antonio, TexasHospital not named in the registry
- Santa Monica, CaliforniaHospital not named in the registry
- Spokane, WashingtonHospital not named in the registry
- Troy, MichiganHospital not named in the registry
- Wilmington, North CarolinaHospital not named in the registry
About the trial
What the trial wants to find out
This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).
The 4 groups in the trial
- ANB032 SC Dose 1Treatment being tested
This arm will receive treatment SC
Treatment: ANB032
- ANB032 SC Dose 2Treatment being tested
This arm will receive treatment SC
Treatment: ANB032
- ANB032 SC Dose 3Treatment being tested
This arm will receive treatment SC
Treatment: ANB032
- PlaceboPlacebo, for comparison
This arm will receive Placebo SC
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis
- Record updated
- 14 February 2025